Based on this observation and considering the high Bcl-2 expression in UM and the occurrence of liver metastases in its natural history, we have evaluated the therapeutic potential of a new experimental Bcl-2/Bcl-XL inhibitor, S44563, in different uveal melanoma Patient-Derived Xenografts (PDXs), and derived-cell lines, alone or in combination with fotemustine. Here, BCL2 is linked to uveal melanoma.